Dividend Stocks to Watch: AbbVie, Amgen, and Gilead Sciences

Top Picks for Dividend Investors: AbbVie, Amgen, and Gilead Sciences offer enticing opportunities. With solid fundamentals and attractive dividend yields, these stocks may benefit income-focused investors in the current market.

Date: 09-02-2025

AI Rating: 7

Earnings Analysis: The report provides insights into AbbVie's revenue growth following the transition from Humira to its successors, Skyrizi and Rinvoq, projecting sales over $31 billion by 2027. Additionally, Gilead Sciences reports a stable revenue stream with a significant free cash flow of $9.4 billion, comfortably covering its $3.9 billion dividend payments in the past year.

Net Income and Profit Margins: While specific net income figures are not disclosed, AbbVie’s past struggles after losing exclusivity on Humira seem to be resolving due to the strong performance of its new products. This may suggest improved profit margins as sales increase.

Free Cash Flow: Gilead Sciences stands out for its robust free cash flow, which supports current dividends and potential future increases.

Return on Equity (ROE): The report does not mention the return on equity for the companies discussed, leaving it out of this analysis. Overall, Gilead appears stable due to its historical dividend growth and free cash flow generation.

Stocks: ABBV AMGN GILD